These suggest that the established method is clinically useful for measuring 4β-OHC and 4α-OHC concentrations in human plasma samples from healthy volunteers as well as CKD patients and would contribute to accurate evaluation of in vivo CYP3A activity. The gene discussed is CYP3A4; the disease is chronic kidney disease.